Trial · NCT01555580
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of GM-CSF in patients with myasthenia gravis | 150 days | The number of subjects experiencing a Class II-V adverse event within 120 days of the start of treatment that is probably or definitely related to the study medication |
| Primary | The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 30 days post-treatment | 30 days | |
| Primary | The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 60 days post-treatment | 60 days | |
| Primary | The change from baseline in the quantitative and functional (suppressive capacity) characterization of circulating regulatory T cells at 120 days post-treatment | 120 days | |
| Secondary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at 60 days | 60 days | |
| Secondary | Change from baseline in the Quantitative Myasthenia Gravis (QMG) score at day 120 | 120 days | |
| Secondary | Change from baseline in the Myasthenia Gravis Composite score at day 60 | 60 days | |
| Secondary | Change from baseline in the Myasthenia Gravis Composite score at day 120 | 120 days | |
| Secondary | Change from baseline in Manual Muscle Testing (MMT) score at day 60 | 60 days | |
| Secondary | Change from baseline in Manual Muscle Testing (MMT) score at day 120 | 120 days | |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 60 | 60 days | |
| Secondary | Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at day 120 | 120 days | |
| Secondary | Change from baseline in Quality of Life Assessment (SF-36) at day 60 | 60 days | |
| Secondary | Change from baseline in Quality of Life Assessment (SF-36) at day 120 | 120 days | |
| Secondary | Change from baseline in acetylcholine receptor antibody titre level at day 60 | 60 days | |
| Secondary | Change from baseline in acetylcholine receptor antibody titre level at day 120 | 120 days | |
| Secondary | Change from baseline in prednisone dose at day 60 | 60 days | |
| Secondary | Change from baseline in prednisone dose at day 120 Days | 120 days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01555580/registered